[{"orgOrder":0,"company":"Cartherics","sponsor":"Shunxi Holding Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"CTH-004","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cartherics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cartherics \/ Shunxi Holding Group","highestDevelopmentStatusID":"5","companyTruncated":"Cartherics \/ Shunxi Holding Group"},{"orgOrder":0,"company":"Cartherics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"CTH-401","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Cartherics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cartherics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Cartherics \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Cartherics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The funding will support the clinical trial for CTH-401, the Company’s lead cell therapy and the only natural killer (NK) cell product currently under development for ovarian cancer.

                          Product Name : CTH-401

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          September 30, 2024

                          Lead Product(s) : CTH-401

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Undisclosed

                          Deal Size : $15.0 million

                          Deal Type : Private Placement

                          blank

                          02

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The agreement provides Shunxi a licence to develop, manufacture and commercialise CTH-004, for the treatment of multiple solid tumours including ovarian cancer in Greater China, as well as an option to negotiate rights to other CAR-T products that incorp...

                          Product Name : CTH-004

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          April 28, 2023

                          Lead Product(s) : CTH-004

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Shunxi Holding Group

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank